Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast

Genes Chromosomes and Cancer

Volumn 51, Issue 12, 2012, Pages 1067-1078

  Liao, Shaoxi ^a   Desouki, Mohamed M ^b   Gaile, Daniel P ^c   Shepherd, Lori ^d   Nowak, Norma J ^d,e   Conroy, Jeffrey ^d   Barry, William T ^a   Geradts, Joseph ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BREAST CARCINOMA; CANCER GROWTH; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; HUMAN TISSUE; MICRODISSECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS;

BACTERIA (MICROORGANISMS);

EID: 84867232961     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21991     Document Type: Article

References (52)

1. Alexopoulou AN, Leao M, Caballero OL, Da Silva L, Reid L, Lakhani SR, Simpson AJ, Marshall JF, Neville AM, Jat PS. 2010. Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res 12: R51.
2. Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Welzl G, Hofler H, Werner M. 2000. Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: Evidence of genetic resemblance by CGH. Int J Cancer 85: 82-86.
3. Bombonati A, Sgroi DC. 2011. The molecular pathology of breast cancer progression. J Pathol 223: 307-317.
4. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W. 1999. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 187: 396-402.
5. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. 2004. Ductal carcinoma in situ of the breast. N Engl J Med 350: 1430-1441.
6. Camacho CP, Latini FR, Oler G, Hojaij FC, Maciel RM, Riggins GJ, Cerutti JM. 2009. Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment. Clin Endocrinol 70: 475-483.
7. Castro NP, Osorio CA, Torres C, Bastos EP, Mourao-Neto M, Soares FA, Brentani HP, Carraro DM. 2008. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 10: R87.
8. Desouki MM, Liao S, Huang H, Conroy J, Nowak NJ, Shepherd L, Gaile DP, Geradts J. 2010. Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach. J Cancer Res Clin Oncol 137: 795-809.
9. Desouki MM, Liao S, Conroy J, Nowak NJ, Shepherd L, Gaile DP, Geradts J. 2011. The genomic relationship between primary breast carcinomas and their nodal metastases. Cancer Invest 29: 300-307.
10. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M. 2011. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: A meta-analysis of individual patient data. Lancet Oncol 12: 1134-1142.
11. Di Pietro C, Rapisarda A, Amico V, Bonaiuto C, Viola A, Scalia M, Motta S, Amato A, Engel H, Messina A, Sichel G, Grzeschik K, Purrello M. 2000. Genomic localization of the human genes TAF1A, TAF1B and TAF1C, encoding TAF(I)48, TAF(I)63 and TAF(I)110 subunits of class I general transcription initiation factor SL1. Cytogenet Cell Genet 89: 133-136.
12. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, Di Palma S, Rilke F. 1994. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 11: 223-235.
13. Farabegoli F, Champeme MH, Bieche I, Santini D, Ceccarelli C, Derenzini M, Lidereau R. 2002. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 196: 280-286.
14. Fleming FJ, Hill AD, McDermott EW, O'Higgins NJ, Young LS. 2004. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J Clin Endocrinol Metab 89: 375-383.
15. Frykberg ER, Bland KI. 1994. Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 74( 1 Suppl): 350-361.
16. Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E. 1996. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 56: 5260-5265.
17. Gaile DP, Miecznikowski J, Shepherd LA, Lui S. 2007. aCGHplus: An R library for the storage, analysis and visualization of aCGH data. Available at: http://sphhp.buffalo.edu/biostat/research/software/acghplus/index.php.
18. Gaile DP, Shepherd LA, Bruno AE, Liu S, Morrison C, Sucheston L, Miecznikowski J. 2010. iGenomicViewer: R package for visualisation of high dimension genomic data. Int J Bioinform Res Appl 6: 584-593.
19. Ghoshal P, Nganga AJ, Moran-Giuati J, Szafranek A, Johnson TR, Bigelow AJ, Houde CM, Avet-Loiseau H, Smiraglia DJ, Ersing N, Chanan-Khan AA, Coignet LJ. 2009. Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer Res 69: 4380-4387.
20. Green AR, Burney C, Granger CJ, Paish EC, El-Sheikh S, Rakha EA, Powe DG, Macmillan RD, Ellis IO, Stylianou E. 2008. The prognostic significance of steroid receptor co-regulators in breast cancer: Co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat 110: 427-437.
21. Hadjantonakis AK, Sheward WJ, Harmar AJ, de Galan L, Hoovers JM, Little PF. 1997. Celsr1, a neural-specific gene encoding an unusual seven-pass transmembrane receptor, maps to mouse chromosome 15 and human chromosome 22qter. Genomics 45: 97-104.
22. Huang HY, Shariat SF, Sun TT, Lepor H, Shapiro E, Hsieh JT, Ashfaq R, Lotan Y, Wu XR. 2007. Persistent uroplakin expression in advanced urothelial carcinomas: Implications in urothelial tumor progression and clinical outcome. Hum Pathol 38: 1703-1713.
23. Hwang ES, DeVries S, Chew KL, Moore DH, 2nd, Kerlikowske K, Thor A, Ljung BM, Waldman FM. 2004. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 10: 5160-5167.
24. Iakovlev VV, Arneson NC, Wong V, Wang C, Leung S, Iakovleva G, Warren K, Pintilie M, Done SJ. 2008. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: A calibrated aCGH study. Clin Cancer Res 14: 4446-4454.
25. James LA, Mitchell EL, Menasce L, Varley JM. 1997. Comparative genomic hybridisation of ductal carcinoma in situ of the breast: Identification of regions of DNA amplification and deletion in common with invasive breast carcinoma. Oncogene 14: 1059-1065.
26. Jiang J, Yu L, Huang X, Chen X, Li D, Zhang Y, Tang L, Zhao S. 2001. Identification of two novel human dynein light chain genes, DNLC2A and DNLC2B, and their expression changes in hepatocellular carcinoma tissues from 68 Chinese patients. Gene 281: 103-113.
27. Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C. 2001. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol 115: 709-718.
28. Li QX, Ke N, Sundaram R, Wong-Staal F. 2006. NR4A1, 2, 3-An orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol Histopathol 21: 533-540.
29. Ludwig L, Kessler H, Hoang-Vu C, Dralle H, Adler G, Boehm BO, Schmid RM. 2003. Grap-2, a novel RET binding protein, is involved in RET mitogenic signaling. Oncogene 22: 5362-5366.
30. Ludwig L, Oswald F, Hoang-Vu C, Dralle H, Hildt E, Schmid RM, Karges W. 2009. Expression of the Grb2-related RET adapter protein Grap-2 in human medullary thyroid carcinoma. Cancer Lett 275: 194-197.
31. Matsumoto K, Satoh T, Irie A, Ishii J, Kuwao S, Iwamura M, Baba S. 2008. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology 72: 444-449.
32. Miecznikowski JC, Gaile DP, Liu S, Shepherd L, Nowak N. 2011. A new normalizing algorithm for BAC CGH arrays with quality control metrics. J Biomed Biotechnol. Article ID 860732, Epub ahead of print February 21.
33. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, Conneely OM. 2007. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med 13: 730-735.
34. Nowak NJ, Miecznikowski J, Moore SR, Gaile D, Bobadilla D, Smith DD, Kernstine K, Forman SJ, Mhawech-Fauceglia P, Reid M, Stoler D, Loree T, Rigual N, Sullivan M, Weiss LM, Hicks D, Slovak ML. 2007. Challenges in array comparative genomic hybridization for the analysis of cancer samples. Genet Med 9: 585-595.
35. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. 1998. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90: 697-703.
36. Olshen AB, Venkatraman ES, Lucito R, Wigler M. 2004. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557-572.
37. Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A. 2005. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21: 3017-3024.
38. Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL. 2007. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Mol Cell Biol 27: 5933-5948.
39. Polyak K, Hu M. 2005. Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia 10: 231-247.
40. Sanders ME, Schuyler PA, Dupont WD, Page DL. 2005. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103: 2481-2484.
41. Shi ZZ, Zhang JW, Zheng S. 2007. What we know about ST13, a co-factor of heat shock protein, or a tumor suppressor? J Zhejiang Univ Sci B 8: 170-176.
42. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, Poller DN. 1996. A prognostic index for ductal carcinoma in situ of the breast. Cancer 77: 2267-2274.
43. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. 2005. Molecular evolution of breast cancer. J Pathol 205: 248-254.
44. Song L, Zlobin A, Ghoshal P, Zhang Q, Houde C, Weijzen S, Jiang Q, Nacheva E, Yagan D, Davis E, Galiegue-Zouitina S, Catovsky D, Grogan T, Fisher RI, Miele L, Coignet LJ. 2005. Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. Cancer Res 65: 4554-4561.
45. van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WF, Sleijfer S, Foekens JA, Dorssers LC. 2009. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Br J Cancer 101: 1824-1832.
46. van de Wiel MA, Kim KI, Vosse SJ, van Wieringen WN, Wilting SM, Ylstra B. 2007. CGHcall: Calling aberrations for array CGH tumor profiles. Bioinformatics 23: 892-894.
47. Wang LB, Zheng S, Zhang SZ, Peng JP, Ye F, Fang SC, Wu JM. 2005. Expression of ST13 in colorectal cancer and adjacent normal tissues. World J Gastroenterol 11: 336-339.
48. Wang C, Iakovlev VV, Wong V, Leung S, Warren K, Iakovleva G, Arneson NC, Pintilie M, Miller N, Youngson B, McCready DR, Done SJ. 2009. Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: An aCGH study. Genes Chromosomes Cancer 48: 1091-1101.
49. Wanschers B, van de Vorstenbosch R, Wijers M, Wieringa B, King SM, Fransen J. 2008. Rab6 family proteins interact with the dynein light chain protein DYNLRB1. Cell Motil Cytoskeleton 65: 183-196.
50. Westfall PH, Young SS. 1993. Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment. New York: Wiley.
51. Yu J, Palmer C, Alenghat T, Li Y, Kao G, Lazar MA. 2006. The corepressor silencing mediator for retinoid and thyroid hormone receptor facilitates cellular recovery from DNA double-strand breaks. Cancer Res 66: 9316-9322.
52. Yu H, Kumar SM, Fang D, Acs G, Xu X. 2007. Nuclear orphan receptor TR3/Nur77 mediates melanoma cell apoptosis. Cancer Biol Ther 6: 405-412.